Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2002-02-21
2009-11-17
Haddad, Maher M (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S144100, C530S388220
Reexamination Certificate
active
07618630
ABSTRACT:
Antagonists of α4 integrin/α4 integrin ligand adhesion, which inhibit the biological effects of such adhesion are described and methods for their use are detailed. Such antagonists are useful in suppressing bone destruction associated with multiple myeloma. The homing of multiple myeloma cells to bone marrow and their α4 integrin-dependent release of bone-resorbing factors, resulting in bone destruction in patients with multiple myeloma, is inhibited.
REFERENCES:
patent: 5217870 (1993-06-01), Hession et al.
patent: 5272263 (1993-12-01), Hession et al.
patent: 5367056 (1994-11-01), Hession et al.
patent: 5510332 (1996-04-01), Kogan et al.
patent: 5695755 (1997-12-01), Papayannopoulou
patent: 5824304 (1998-10-01), Papayannopoulou
patent: 5840299 (1998-11-01), Bendig et al.
patent: 5843438 (1998-12-01), Papayannopoulou
patent: 5871734 (1999-02-01), Lobb et al.
patent: 5885786 (1999-03-01), Cabot
patent: 5888507 (1999-03-01), Burkly
patent: 5932214 (1999-08-01), Lobb et al.
patent: 6252043 (2001-06-01), Hession et al.
patent: 6307025 (2001-10-01), Hession et al.
patent: 6602503 (2003-08-01), Lobb et al.
patent: 6632927 (2003-10-01), Adair et al.
patent: 6692742 (2004-02-01), Nakamura et al.
patent: 7211252 (2007-05-01), Mundy et al.
patent: 2002/0022028 (2002-02-01), Mundy et al.
patent: 2002/0041874 (2002-04-01), Mundy et al.
patent: WO 90/13300 (1990-11-01), None
patent: WO 93/13798 (1993-07-01), None
patent: WO 93/15764 (1993-08-01), None
patent: WO 94/11027 (1994-05-01), None
patent: WO 94/16094 (1994-07-01), None
patent: WO 94/17828 (1994-08-01), None
patent: 95/19790 (1995-07-01), None
patent: WO 99/61421 (1999-12-01), None
patent: WO 00/15247 (2000-03-01), None
patent: WO 01/12186 (2001-02-01), None
patent: 97/49428 (2007-12-01), None
Amit et al., Three-dimensional structure of an antigen-antibody complex at 2.8 A resolution. Science. 233(4765):747-753, 1986.
Rudikoff et al. Single amino acid substitution altering antigen-binding specificity. Proc Natl Acad Sci U S A. Mar. 1982;79(6):1979-83.
Lokhorst HM, et al Primary tumor cells of myeloma patients induce interleukin-6 secretion in long-term bone marrow cultures. Blood. 84(7):2269-77, 1994.
van Zaanen HC, et al Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study. Br J Haematol.;102(3):783-90, Aug. 1998.
Kamata et al. Identification of putative ligand-binding sites of the integrin alpha 4 beta 1 (VLA-4, CD49d/CD29) Biochem J. 305 Pt 3):945-51. Erratum in: Biochem J 317(Pt 3):959, 1996.
Alexanian R et al Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA. Jun. 2, 1969;208(9):1680-5.
Owens RJ, Young RJ. The genetic engineering of monoclonal antibodies. J Immunol Methods. 168(2):149-165, 1994.
Masellis-Smith et al. “Adhesion of Multiple Myeloma Peripheral B Cells to Bone Marrow Fibroblasts: A Requirement of CD44 and α4β7”, Cancer Research 57(5): 930-936 (1997).
Roodman GD “Mechanisms of Bone Lesions in Multiple Myeloma and Lymphoma”,Database Medline ′Online!: US National Library of Medicine (NLM), Bethesda, MD, US, retrieved from STN, Database accession No. 1998026745, abstract.
Roodman GD “Mechanisms of Bone Lesions in Multiple Myeloma and Lymphoma”,Cancer80 (8 Suppl): 1557-1563 (Oct. 15, 1997).
Akatsu et al.“Chinese Hamster Ovary Cells Expressing Alpha4beta1 Integrin Stimulate Osteoclast Formation In Vitro”,Database BIOSIS ′Online!: Biosciences Information Service, Philadelphia, PA, US, (Aug. 1998) Database accession No. PREV199800429141, abstract.
Akatsu et al.“Chinese Hamster Ovary Cells Expressing α4β1Integrin Stimulate Osteoclast Formation In Vitro”,Journal of Bone and Mineral Research13 (8): 1251-1259 (1998).
Michigami et al. “Interactions of Myeloma Cells with Bone Marrow Stromal Cells via Alpha4 Beta1 Integrin—VCAM-1 is required for the Development of Osteolysis”,Database SCISEARCH ′Online!, retrieved form STN, Database accession No. 684996.
Mori et al. “Antiα4 Integrin Antibody Suppresses the Bone Disease of Myeloma and Disrupts Myeloma-marrow Stromal Cell Interactions”,Journal of Bone and Mineral Research14 Supp. 1, p. S173, Abstract 1161 (1999).
Damiano et al., “Integrin-Mediated Drug Resistance in Multiple Myeloma”, 2000, Leukemia and Lymphama, vol. 38 (1-2):71-81.
Damiano et al., “Cell Adhesion Mediated Drug Resistance (CAM-DR): Role of Integrins . . . ”, Mar. 1, 1999, Blood, vol. 93(5):1658-1667.
Mundry et al., “Stromal cells regulate survival of B-lineage leukemic cells . . . ”, Sep. 1, 2000, Blood, vol. 96 (5):1926-1932.
Alsina, M. et al., “Development of an In Vivo Model of Human Multiple Myeloma Bone Disease,”Blood87: 1495-1501 (1996).
Attal, M. et al., “A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma,”N Engl J Med335: 91-97 (1996).
Atkins, C., “Correspondence: High-Dose Chemotherapy in Multiple Myeloma,”N. Engl J Med335: 1844 (1996).
Oivanen, T. M. et al., “Correspondence: High-Dose Chemotherapy in Multiple Myeloma,”N Eng J Med335: 1844-1845 (1996).
Attal, M. et al., “Correspondence: High-Dose Chemotherapy in Multiple Myeloma—In Reply,”N Engl J Med335: 1844-1845 (1996).
Barlogie, B. et al., “Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients,”Blood98: 492-494 (2001).
Bataille, R. et al. “Serum Levels of Interleukin 6, a Potent Myeloma Cell Growth Factor, as a Reflect of Disease Severity in Plasma Cell Dyscrasias,”J Clin Invest84: 2008-2011 (1989).
Bataille, R. et al., “Mechanisms of Bone Lesions in Multiple Myeloma,”Hematology/Oncology Clinics of North America6: 285-295 (1992).
Bataille, R. et al., “Biologic Effects of Anti-Interleukin-6 Murine Monoclonal Antibody in Advanced Multiple Myeloma,”Blood86: 685-691 (1995).
Berenson, J. R. et al., “Long-Term Pamidronate Treatment of Advanced Multiple Myeloma Patients Reduces Skeletal Events,”J Clin Oncol16: 593-602 (1998).
Seymour, J.F., “Correspondence; Long-Term Pamidronate in Multiple Myeloma,”J CLIN ONCOL16: 2572 (1998).
Berenson, J. R., “Correspondence: Long-Term Pamidronate in Multiple Myeloma—In Reply,”J CLIN ONCOL16: 2572-2573 (1998).
Boyce, B. F. et al., “Bolus Injections of Recombinant Human Interleukin-1 Cause Transient Hypocalcemia in Normal Mice,”Endocrinology125: 2780-2783 (1989).
Chauhan, D. et al., “Regulation of Interleukin 6 in Multiple Myeloma and Bone Marrow Stromal Cells,”Stem Cells13 (suppl 2): 35-39 (1995).
Dallas, S. L. et al., “Ibandronate Reduces Osteolytic Lesions but not Tumor Burden in a Murine Model of Myeloma Bone Disease,” Blood 93: 1697-1706 (1999).
Epstein, J., “Myeloma Phenotype: Clues To Disease Origin and Manifestation,”Hematology/Oncology Clinics of North America6:249-256 (1992).
Garrett, I. R. et al., “A Murine Model of Human Myeloma Bone Disease,” Bone 20: 515-520 (1997).
Gosslar, U. et al., “Predominant Role of α4-integrins for distinct steps of lymphoma metastasis,”Proc. Natl. Acad. Sci. USA93: 4821-4826 (1996).
MacDonald, B. R. et al., “Effects of Human Recombinant CSF-GM and Highly Purified CSF-1 on the Formation of Multinucleated Cells with Osteoclast Characteristics in Long-Term Bone Marrow Cultures,”J Bone and Mineral Research1: 227-233 (1986).
Matsuura, N. et al., “Induction of Experimental Bone Metastasis in Mice by Tranfection of Integrin α4β1 into Tumor Cells,”Am J Pathol148: 55-61 (1996).
Michigami, T. et al., “Interactions of Myeloma Cells with Bone Marrow Stromal Cells Via α4&
Mundy Gregory R.
Yoneda Toshiyuki
Board of Regents , The University of Texas System
Haddad Maher M
Steptoe & Johnson LLP
LandOfFree
Methods of treating multiple myeloma and myeloma-induced... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating multiple myeloma and myeloma-induced..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating multiple myeloma and myeloma-induced... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4100800